English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Plasma thrombomodulin (TM), a marker of disease activity and endothelial damage, was measured in follow up of patients with systemic lupus erythematosus (SLE). Plasma levels of TM were measured by ELISA method using the mouse antithrombomodulin monoclonal antibody in the group of 52 lupus patients. Disease activity was assessed by European Consensus Lupus Activity Measurement (ECLAM) and levels of anti-dsDNA antibodies and C3 and C4 complement components were investigated. Correlation between thrombomodulin plasma levels and disease activity index was found (r = 0.69 p = 0.00001). Stable and low levels of TM were found in the subgroup of patients with low stabile disease x = 32.0 (± 11.56) ng/ml with no trend to significant change. In the subgroup

SERIAL FOLLOW UP OF SOLUBLE THROMBOMODULIN LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS